icnsa:mhMe esevecilt tsgneroe rcoeetpr troloadmu R)EM(S atth satc sa an nittnagsao on hte regontse spocertre of eth bearts adn tacs as an aiplrta igtaosn on resntego rpecresot ni beno adn u.ruset ehfeor,rTe ↑ kris fo oldnetimera rencca nda ↑ iskR of ietneru samorca
s:seU ER ro RP vteioips urosmt rbe()sat
Whole point of administering a SERM after breast cancer is to reduce risk of recurrence. Increased estrogen exposure is associated with increased risk of breast cancer (per FA 2019 p. 636). So you're looking for something that is an estrogen antagonist at the breast, which narrows it down to B and C right off the bat.